Genetic Analysis AS
This article was originally published in Start Up
A number of diseases are associated with or influenced by imbalances in gut bacteria, including autism and GI disorders such as ulcers, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, colon cancer, and necrotizing enterocolitis in preterm infants. Many other conditions not obviously associated with the gastrointestinal tract also seem to be influenced by imbalance in the gut, such as allergies, eczema, depression and obesity. Genetic Analysis is developing the G-MAP, a microbiota array technology that analyzes and profiles the gut microflora and associates the resulting profile with various diseases.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target the GI Tract," features profiles of Alvine Pharmaceuticals, Genetic Analysis, Meritage Pharma and Ventrus Biosciences. Plus these Start-Ups Across Health Care: Advanced Cardiac Therapeutics, Concert Pharmaceuticals, ImThera Medical, On-Q-ity and Telormedix.
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.